Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity

References

• Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772–83
   PubMed Web of Science ®Google Scholar
• Cartier A, Lemieux I, Alméras N, Tremblay A, Bergeron J, Després JP. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 2008; 93: 1931–8
   Web of Science ®Google Scholar
• Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol. 1987; 139: 1546–9
   PubMed Web of Science ®Google Scholar
• Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?. J Clin Endocrinol Metab. 2002; 87: 1184–8
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes. 2003; 52: 1104–10
   PubMed Web of Science ®Google Scholar
• Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A. 1996; 93: 11008–13
   PubMed Web of Science ®Google Scholar
• Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997; 99: 2930–40
   PubMed Web of Science ®Google Scholar
• Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002; 13: 323–40
   PubMed Web of Science ®Google Scholar
• Dayer JM, Bresnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum. 2002; 46: 574–8
   PubMed Web of Science ®Google Scholar
• Ueland T, Kristo C, Godang K, Aukrust P, Bollerslev J. Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. J Clin Endocrinol Metab. 2003; 88: 1492–6
   Google Scholar
• Lohman T, Roche A, Martorell R. Measurement descriptions and techniques. Anthropometric standardization reference manual, G Steigelman. Human Kinetics, Champaign, IL 1988; 1–71
   Google Scholar
• van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord. 1993; 17: 187–96
   PubMed Web of Science ®Google Scholar
• Ferland M, Després JP, Tremblay A, Pinault S, Nadeau A, Moorjani S, et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr. 1989; 61: 139–48
   PubMed Web of Science ®Google Scholar
• Richterich R, Dauwalder H. Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method]. Schweiz Med Wochenschr. 1971; 101: 615–8
   PubMedGoogle Scholar
• Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab. 1971; 33: 732–8
   PubMed Web of Science ®Google Scholar
• Burstein M, Samaille J. On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins]. Clin Chim Acta. 1960; 5: 609
   PubMed Web of Science ®Google Scholar
• Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966; 15: 45–52
   PubMed Web of Science ®Google Scholar
• Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem. 1998; 35(Pt 6)745–53
   PubMedGoogle Scholar
• Fain JN, Tichansky DS, Madan AK. Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism. 2006; 55: 1113–21
   PubMed Web of Science ®Google Scholar
• Saltevo J, Vanhala M, Kautiainen H, Laakso M. Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood. Diab Vasc Dis Res. 2007; 4: 328–31
   Google Scholar
• Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med. 2003; 198: 877–88
   PubMed Web of Science ®Google Scholar
• Somm E, Cettour-Rose P, Asensio C, Charollais A, Klein M, Theander-Carrillo C, et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia. 2006; 49: 387–93
   PubMed Web of Science ®Google Scholar
• Ruotsalainen E, Salmenniemi U, Vauhkonen I, Pihlajamaki J, Punnonen K, Kainulainen S, et al. Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care. 2006; 29: 2714–20
   PubMed Web of Science ®Google Scholar
• Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM, et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes. 2005; 54: 3503–9
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Somm E, Chicheportiche R, Burger D, Pernin A, Cuenod-Pittet B, et al. Regulatory effects of interleukin (IL)-1, interferon-beta, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab. 2004; 89: 2652–8
   Google Scholar
• Gabay C, Dreyer M, Pellegrinelli N, Chicheportiche R, Meier CA. Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. J Clin Endocrinol Metab. 2001; 86: 783–91
   PubMed Web of Science ®Google Scholar
• Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci U S A. 1999; 96: 7047–52
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Meier CA. Immunomodulatory actions of leptin. Mol Cell Endocrinol. 2002; 194: 1–7
   Google Scholar
• Doerrler W, Feingold KR, Grunfeld C. Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms. Cytokine. 1994; 6: 478–84
   Google Scholar
• Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol. 1985; 135: 3969–71
   PubMedGoogle Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796–808
   PubMed Web of Science ®Google Scholar
• Sherry CL, Kramer JM, York JM, Freund GG. Behavioral recovery from acute hypoxia is reliant on leptin. Brain Behav Immun. 2009; 23: 169–75
   Google Scholar
• Salmenniemi U, Ruotsalainen E, Pihlajamaki J, Vauhkonen I, Kainulainen S, Punnonen K, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004; 110: 3842–8
   PubMed Web of Science ®Google Scholar
• Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, Laakso M. Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome. Mediators Inflamm. 2007; 2007: 93573
   PubMed Web of Science ®Google Scholar